GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Intangible Assets

AVBP (ArriVent BioPharma) Intangible Assets : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. ArriVent BioPharma's intangible assets for the quarter that ended in Sep. 2024 was $0.00 Mil.


ArriVent BioPharma Intangible Assets Historical Data

The historical data trend for ArriVent BioPharma's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Intangible Assets Chart

ArriVent BioPharma Annual Data
Trend Dec21 Dec22 Dec23
Intangible Assets
- - -

ArriVent BioPharma Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

ArriVent BioPharma Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


ArriVent BioPharma  (NAS:AVBP) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


ArriVent BioPharma Intangible Assets Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


ArriVent BioPharma Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.